Tizaglenn Co 12 Μg/ 250 Μg 12 μg/ 250 μg Powder for inhalation (capsules).
PDF Leaflet Revision Date: 27 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Regular treatment of bronchial asthma in adults over 18 years.
Dosage (summary)
One capsule by oral inhalation every 12 hours for adults.
Onset of Action / Duration
Onset: 1-3 mins, Duration: at least 12 hours
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- CYP3A4 inhibitors
- Non-potassium sparing diuretics
- Beta blockers
Contraindications
- Hypersensitivity to components
Common side effects
- Oral candidiasis
- Headache
- Tremor
- Palpitations
Counselling Points
- Use regularly even when asymptomatic
- Rinse mouth after use
- Monitor for worsening asthma symptoms
Serious warnings
- Not for acute asthma symptoms
- Risk of paradoxical bronchospasm
- Potential for hypokalaemia
Important Disclaimer
The Tizaglenn Co 12 Μg/ 250 Μg 12 μg/ 250 μg Powder for inhalation (capsules). professional information leaflet below is the property of Glenmark Pharmaceuticals South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
